Precision Biosciences (DTIL) Non-Current Deffered Revenue (2018 - 2025)

Precision Biosciences (DTIL) has 8 years of Non-Current Deffered Revenue data on file, last reported at $20.0 million in Q3 2025.

• Non-Current Deffered Revenue for Q3 2025 came in at $20.0 million, down 24.92% year-over-year; the trailing twelve-month figure through Sep 2025 was $20.0 million (down 24.92% YoY), and the FY2024 annual result was $23.3 million, down 68.12% from the prior year.
• Non-Current Deffered Revenue fell to $20.0 million in Q3 2025 per DTIL's latest filing, from $20.2 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $131.2 million in Q1 2021 and troughed at $20.0 million in Q3 2025.
• A 5-year average of $63.6 million and a median of $73.1 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2021 and 2025: Non-Current Deffered Revenue jumped 99.05% in 2021, then slumped 72.58% in 2025.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $67.0 million in 2021, then increased by 23.66% to $82.9 million in 2022, then retreated by 11.81% to $73.1 million in 2023, then tumbled by 68.12% to $23.3 million in 2024, then retreated by 14.35% to $20.0 million in 2025.
• Business Quant data shows DTIL's Non-Current Deffered Revenue at $20.0 million in Q3 2025, $20.2 million in Q2 2025, and $20.5 million in Q1 2025.